financetom
Business
financetom
/
Business
/
Australia's Star Entertainment expects to get liquidity offers, shares slump on pending results
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Australia's Star Entertainment expects to get liquidity offers, shares slump on pending results
Feb 27, 2025 4:39 PM

(Reuters) - Casino operator Star Entertainment said on Friday it is expecting to receive one or more liquidity proposals during the day, with its first-half results only to be finalised if those offers sufficiently address its cash-crunch.

Shares of the company fell 11.5% to A$0.12 as of 0002 GMT.

Trading in Star shares was temporarily halted by the Australian Stock Exchange earlier in the day, pending an announcement.

"It is likely that the 1HFY25 report will only be able to be finalised if the company has received liquidity proposals which, after appropriate consideration by the directors, are sufficiently capable of being progressed to finalisation in the context of determining whether the company can continue as a going concern," Star said in a statement.

This month, Star Entertainment said that U.S.-based Oaktree had offered to refinance A$650 million ($405.08 million) of its debt, in what could be a major lifeline for the cash-strapped firm.

Star said it was considering the offer but did not guarantee that the proposal would be accepted.

If the offer is approved, it would result in the shareholding dilution of the casino operator's investors, making Oaktree a significant investor in the future.

Star, which has casinos entangled in a web of regulations even as its cash reserves deplete and bills stack up, is due to release its first-half results on Friday.

The company is expected to report an underlying loss of A$79.5 million for the six months ended December 31, according to Visible Alpha consensus estimates.

If Star is unable to publish results by the end of the day, trading in its shares will be suspended from Monday, the company said.

($1 = 1.6046 Australian dollars)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Delaware judge says she will not block Metsera from ending Pfizer deal 
Delaware judge says she will not block Metsera from ending Pfizer deal 
Nov 5, 2025
WILMINGTON, Delaware, Nov 5 (Reuters) - A Delaware judge said on Wednesday she would reject a request by Pfizer ( PFE ) to temporarily block Metsera ( MTSR ) from terminating its takeover deal with Pfizer ( PFE ), allowing Metsera ( MTSR ) to proceed instead with a higher $10 billion deal from Novo Nordisk. ...
World Kinect Corporation Completes Acquisition of Universal Weather and Aviation's Trip Support Services Business
World Kinect Corporation Completes Acquisition of Universal Weather and Aviation's Trip Support Services Business
Nov 5, 2025
MIAMI--(BUSINESS WIRE)-- World Kinect Corporation ( WKC ) today announced that it has completed its previously announced acquisition of the Trip Support Services (TSS) division of Universal Weather and Aviation. Universal Weather, headquartered in Houston, Texas, has been a pioneer in trip support services with deep expertise in international travel regulations, logistics, and supply chain management. Its trip support business...
Jazz Pharmaceuticals Q3 revenue beats estimates
Jazz Pharmaceuticals Q3 revenue beats estimates
Nov 5, 2025
Overview * Jazz Pharmaceuticals ( JAZZ ) Q3 revenue grows 7% yr/yr, beating analyst expectations * Adjusted EPS for Q3 beats consensus, reflecting robust operational performance * Company narrows 2025 revenue guidance to $4.175 - $4.275 bln Outlook * Company narrows 2025 revenue guidance to $4.175 - $4.275 bln * Jazz Pharmaceuticals ( JAZZ ) expects top-line data from zanidatamab...
Cardiac muscle therapeutics firm Cytokinetics Q3 net loss widens
Cardiac muscle therapeutics firm Cytokinetics Q3 net loss widens
Nov 5, 2025
Overview * Cytokinetics ( CYTK ) Q3 net loss widens to $306.2 mln, driven by debt conversion expense * Company reports Q3 revenue of $1.9 mln, up from $0.5 mln last year * Cytokinetics ( CYTK ) prepares for potential U.S. launch of aficamten pending FDA approval Outlook * Company expects EMA decision on aficamten MAA in 1H 2026 *...
Copyright 2023-2026 - www.financetom.com All Rights Reserved